In summary, a dysfunctional immune response is expected because of the reduction in antigen presentation by tumor cells and the decrease in the number of T and NK cells, which result in disease progression and no change in the serum levels of sLAG-3 and sPD-L1 after treatment, thus generating treatment resistance. The gene discussed is LAG3; the disease is neoplasm.